Sorafenib (Nexavar) is a targeted therapy acting as VEGFR and PDGFR tyrosine-kinase inhibitor that has been approved in France in the treatment of metastatic renal cell carcinoma and hepatocarcinoma. Hand-foot syndrome is one of the more frequent toxicity related to sorafenib. This paper up lights the main points concerning this toxicity in the view of specialists working together in the care of these patients: a pharmacologist, a dermatologist and a medical oncologist. The clinic and symptoms of hand-foot syndrome as the biological interpretation, the symptomatic treatment and the impact on the specific treatment of sorafenib are developed.